Methyl-diethylaminomethylsulfid | 61940-56-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫半缩醛胺衍生物
• 英文名称: Methyl-diethylaminomethylsulfid
• 英文别名: diethyl-(methylsulfanyl-methyl)-amine；Diaethylamino-dimethylsulfid；Methyl-diaethylaminomethyl-sulfid；Diaethyl-(methylmercapto-methyl)-amin；N-Ethyl-N-[(methylsulfanyl)methyl]ethanamine；N-ethyl-N-(methylsulfanylmethyl)ethanamine
• CAS: 61940-56-5
• 化学式: C₆H₁₅NS
• 分子量: 133.258
• InChiKey: OFKMJTXGZQSFBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  28.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Methyl-diethylaminomethylsulfid 、 碘乙烷 生成 triethyl-(methylsulfanyl-methyl)-ammonium; iodide
  参考文献：
  名称：

  Renshaw; Searle, Journal of the American Chemical Society, 1937, vol. 59, p. 2057

  摘要：

  DOI：
• 作为产物：
  描述：

  聚合甲醛 、 甲硫醇 、 二乙胺 在 水 、 potassium carbonate 作用下， 生成 Methyl-diethylaminomethylsulfid
  参考文献：
  名称：

  Renshaw; Searle, Journal of the American Chemical Society, 1937, vol. 59, p. 2057

  摘要：

  DOI：

文献信息

• METHOD FOR PREPARING METHIONINE ANALOGUES
  申请人：ADISSEO FRANCE S.A.S.

  公开号：US20200283387A1

  公开（公告）日：2020-09-10

  The invention relates to a method for preparing a compound (I) or one of the salts thereof, and the uses of said method, R 1 OOC—C(═X)—CHR 2 R 3 (I), wherein X is selected among O; N—R′, wherein R′ is H or a C1-C6 alkyl; and N—OR″ wherein R″ is H, or a C1-C6 alkyl or an alkylaryl; R 1 is H or a C1-C6 alkyl group; R 2 is H, a C1-C6 alkyl, or an alkylaryl; and R 3 is CH 2 SR 4 or CH 2 SeR 4 , where R 4 is H or a C1-C6 alkyl from a compound (II), or one of the salts thereof, R 1 OOC—C(═X)—CHR 2 R 5 and R 5 is H or COOR 6 , where R 6 is H or a C1-C6 alkyl, said method being carried out in the presence of a compound (III) CH 2 (Y)(Z). Wherein Y is H; OR 7 , where R 7 is H, a C1-C6 alkyl or an acyl with formula CO—R 4 ; SR 4 or SeR 4 where R 4 matches the preceding definition; or 1 NR 8 R 9 , where R 8 and R 9 , identical or different, each or together are a C1-C6 alkyl, or an alkylaryl; Z, identical or different to Y, is OR 10 where R 10 is H, a C1-C6 alkyl or CO—R 4 ; a cyclic or acyclic N(COR 4 )(COR 4 ) group; or NR 11 R 12 , where R 11 and R 12 , identical or different, each or together are a C1-C6 alkyl or an alkylaryl; wherein Y and Z together are ═O; said method involving an intermediate product (IV) R 1 OOC—C(═X)—CHR 2 —CH 2 Z.

  该发明涉及一种制备化合物(I)或其盐之一的方法，以及所述方法的用途，其中R1OOC—C(═X)—CHR2R3(I)，其中X在O；N—R′中选择，其中R′为H或C1-C6烷基；和N—OR″其中R″为H，或C1-C6烷基或烷基芳基；R1为H或C1-C6烷基基团；R2为H，C1-C6烷基或烷基芳基；R3为CH2SR4或CH2SeR4，其中R4为H或C1-C6烷基，来自化合物(II)或其盐之一，R1OOC—C(═X)—CHR2R5和R5为H或COOR6，其中R6为H或C1-C6烷基，所述方法在化合物(III)CH2(Y)(Z)的存在下进行。其中Y为H；OR7，其中R7为H，C1-C6烷基或具有CO—R4公式的酰基；SR4或SeR4，其中R4符合前述定义；或1 NR8R9，其中R8和R9，相同或不同，单独或共同为C1-C6烷基或烷基芳基；Z，与Y相同或不同，为OR10，其中R10为H，C1-C6烷基或CO—R4；一个环状或非环状N(COR4)(COR4)基团；或NR11R12，其中R11和R12，相同或不同，单独或共同为C1-C6烷基或烷基芳基；其中Y和Z共同为═O；所述方法涉及中间产物(IV)R1OOC—C(═X)—CHR2—CH2Z。
• KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
  申请人：Amgen Inc.

  公开号：US20210009577A1

  公开（公告）日：2021-01-14

  Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  本文提供KRAS G12C抑制剂，其组成，以及使用方法。这些抑制剂对于治疗多种疾病有用，包括胰腺癌，结直肠癌和肺癌。
• PROCÉDÉ DE PRÉPARATION D'ANALOGUES DE LA MÉTHIONINE
  申请人：Adisseo France S.A.S.

  公开号：EP3405452A1

  公开（公告）日：2018-11-28
• RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS
  申请人：Waters Technologies Corporation

  公开号：US20160139136A1

  公开（公告）日：2016-05-19

  Reagents comprising MS active, fluorescent molecules with an activated functionality for reaction with amines useful in tagging biomolecules such as N-glycans and uses thereof are taught and described.
• Use of Disulfiram for Inflammatory Breast Cancer Therapy
  申请人：Duke University

  公开号：US20170020828A1

  公开（公告）日：2017-01-26

  Methods, compositions of matter, and kits for treatment of breast cancer, and in particular for inflammatory breast cancer, in a patient are disclosed. The methods can include administering a redox modulating agent to the patient. The redox modulating agent can be disulfiram.